3124 related articles for article (PubMed ID: 27440829)
21. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
[TBL] [Abstract][Full Text] [Related]
22. Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition.
Tsimihodimos V; Filippatos TD; Filippas-Ntekouan S; Elisaf M
Curr Vasc Pharmacol; 2017; 15(2):96-102. PubMed ID: 27748201
[TBL] [Abstract][Full Text] [Related]
23. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
24. Knockout of Na
Song P; Huang W; Onishi A; Patel R; Kim YC; van Ginkel C; Fu Y; Freeman B; Koepsell H; Thomson S; Liu R; Vallon V
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F207-F217. PubMed ID: 31091127
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
Gangadharan Komala M; Gross S; Mudaliar H; Huang C; Pegg K; Mather A; Shen S; Pollock CA; Panchapakesan U
PLoS One; 2014; 9(11):e108994. PubMed ID: 25369239
[TBL] [Abstract][Full Text] [Related]
26. EMPA-REG OUTCOME: The Nephrologist's Point of View.
Wanner C
Am J Cardiol; 2017 Jul; 120(1S):S59-S67. PubMed ID: 28606346
[TBL] [Abstract][Full Text] [Related]
27. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
[TBL] [Abstract][Full Text] [Related]
28. Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.
Fioretto P; Avogaro A
Expert Opin Pharmacother; 2017 Apr; 18(5):517-527. PubMed ID: 28277831
[TBL] [Abstract][Full Text] [Related]
29. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
[TBL] [Abstract][Full Text] [Related]
30. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence.
Davidson JA
Postgrad Med; 2019 May; 131(4):251-260. PubMed ID: 30929540
[TBL] [Abstract][Full Text] [Related]
31. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
32. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
33. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
Cherney DZ; Perkins BA; Soleymanlou N; Maione M; Lai V; Lee A; Fagan NM; Woerle HJ; Johansen OE; Broedl UC; von Eynatten M
Circulation; 2014 Feb; 129(5):587-97. PubMed ID: 24334175
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
35. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
Cherney DZI; Cooper ME; Tikkanen I; Pfarr E; Johansen OE; Woerle HJ; Broedl UC; Lund SS
Kidney Int; 2018 Jan; 93(1):231-244. PubMed ID: 28860019
[TBL] [Abstract][Full Text] [Related]
36. EMPA-REG OUTCOME: The Nephrologist's Point of View.
Wanner C
Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179
[TBL] [Abstract][Full Text] [Related]
37. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.
Skrtić M; Yang GK; Perkins BA; Soleymanlou N; Lytvyn Y; von Eynatten M; Woerle HJ; Johansen OE; Broedl UC; Hach T; Silverman M; Cherney DZ
Diabetologia; 2014 Dec; 57(12):2599-602. PubMed ID: 25280671
[No Abstract] [Full Text] [Related]
38. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
39. SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.
Kawanami D; Matoba K; Takeda Y; Nagai Y; Akamine T; Yokota T; Sango K; Utsunomiya K
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28524098
[TBL] [Abstract][Full Text] [Related]
40. Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications.
Castañeda AM; Dutra-Rufato A; Juarez MJ; Grosembacher L; Gonzalez-Torres H; Musso CG
Int Urol Nephrol; 2021 Feb; 53(2):291-299. PubMed ID: 32767250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
